SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the cancellation of purchase orders by Celestial AI, now owned by Marvell, which cited a breach of confidentiality obligations regarding shipping disclosures. The community is sharply divided, with bulls pointing to the company's solid underlying technology and cash position as reasons to buy the dip, while critics and short-sellers argue that management's communication failures and delayed disclosure have severely damaged institutional trust and long-term viability.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science is experiencing high retail interest and significant volatility driven by its extremely low float and speculative social media buzz. Community members are actively debating the potential for a short squeeze, while others warn of the risks associated with the stock's history of dilution and weak financial performance.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors debate the company's turnaround progress under leadership, fueled by recent earnings reports and strategic expansion efforts into home services and fintech assets. The community is actively divided between those who believe the revamped business model and leadership offer long-term value and skeptics concerned about historical performance, dilution, and the sustainability of the company's operational trajectory.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently the subject of intense community debate as investors weigh strong AI-driven earnings growth and favorable analyst ratings against a recent class-action investigation concerning supply chain news. While many traders view the current volatility as a buying opportunity for a key player in the AI hardware buildout, others remain cautious of price manipulation and the stock's recent struggle to reclaim the $300 level.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as it deepens its footprint in the AI infrastructure race through reports of a massive potential investment in Anthropic and the development of specialized TPU chips to challenge current hardware monopolies. Investors are closely tracking these developments alongside upcoming earnings, fueling community discussions around Alphabet's ability to maintain its AI dominance and cloud-segment growth.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing intense downward pressure and widespread investor frustration as the stock hits fresh lows, with many in the community debating whether the company is headed for bankruptcy, a reverse split, or a potential take-private deal. While some bulls remain focused on the potential of upcoming vehicle launches and backing from major strategic partners, bears continue to point to relentless dilution and significant cash burn as ongoing red flags.

Our vision is to create a global exchange using Ethereum blockchain, where everyone on this planet has the opportunity to buy and sell mobile bandwidth in any country just like you buy foreign currencies on FOREX.

DENT

DENT is currently driving heated debate across social platforms, with some users anticipating an explosive breakout and others dismissing it as a volatile asset. The community is actively tracking technical patterns and future potential, while keeping a close eye on broader market momentum.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca Inc. is facing intense market scrutiny following an 8-K filing that disclosed a patient death in its Phase 1 oncology trial, fueling investor concerns over drug toxicity and trial management. While some retail traders are debating whether the price drop presents a buying opportunity, many community members are aggressively rotating into competitors like Revolution Medicines ($RVMD), citing superior safety profiles and clearer acquisition prospects.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors weigh its role as a defensive hedge against market volatility, with ongoing community discussion focused on its dividend reliability and long-term brand durability. While the stock continues to attract interest as a stable income generator, traders are actively monitoring technical support levels and broader sector rotations that could impact near-term price momentum.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility driven by intense short squeeze speculation, high trading volume, and community enthusiasm surrounding its role as a key decentralized exchange on the Solana blockchain. Investors are actively debating the potential for long-term growth versus profit-taking, while tracking technical patterns and the platform's ability to maintain upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays

Barclays raised shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and set a $45.00 price target for the company in a report on Monday...

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Here's What Happened

Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High - Time to Buy...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com...

Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX

Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,618 shares of the biopharmaceutical company's stock...

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment

Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an...

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume  - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Celldex Therapeutics (NASDAQ:CLDX) Shares Cross Above 200-Day Moving Average - Time to Sell...

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research

Wolfe Research raised shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 price objective on the stock in a research report on Monday...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Current Price	$33.66
Prev Close	$33.29
Open	$33.15
Dividend Yield	0.00%
50-Day Moving Average	$30.36
Beta	1.14
Avg. Volume	1.02M
PE Ratio	-8.64

52-Week High	$35.79
52-Week Low	$17.85
Market Capitalization	$2.61B
EPS (Annual)	-$3.90
Price to Book	4.25
Revenue Per Employee	$7,803.03

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDXCelldex Therapeutics Inc.